Pacgen Life Science Corporation, a life science company, focuses on commercializing life sciences products and services. It engages in the development, commercialization, and licensing of PAC-113, an antifungal that contains 12 amino-acid antimicrobial peptide derived from naturally occurring protein found in human saliva for the treatment of oral diseases, such as oral cavity, oral candidiasis, and esophagus infection. The company was formerly known as Pacgen Biopharmaceuticals Corporation and changed its name to Pacgen Life Science Corporation in May 2012. Pacgen Life Science Corporation was founded in 2004 and is headquartered in Vancouver, Canada.
pacgen life science corp
(PBS:TSX Venture Exchange)
701 West Georgia Street
Vancouver, BC V7Y 1C6
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for PBS.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact PACGEN LIFE SCIENCE CORP, please visit www.pacgenlife.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.